NMS-E973 (60 mg/kg; i.v.) inhibits the growth of A375 tumors subcutaneously or intracranially implanted in mice.
NMS-E973 exhibits moderate elimination half-lives (5.55±1.07 h) due to high plasma clearance (39.9±1.70 mL/min/kg) combined with large volumes of distribution (5.83±3.18 L/kg) following intravenous administration (10 mg/kg) in mice.
Animal Model: |
Balb/c male nude mice (aged 6 to 8 weeks) xenografted with the A375 tumors |
Dosage: |
60 mg/kg |
Administration: |
Administered twice daily i.v. according to 2 schedules: (i) every other day for 12 days and (ii) 3 days on/1 day off/3 days on (3-1-3, one cycle). |
Result: |
Both schedules resulted in tumor shrinkage and TGI of 74% and 89%, respectively. |